Given that FXI deficiency comes with a highly variable bleeding risk, mostly associated with trauma/surgery, the safety profile of anti-FXI(a) agents needs to be much more firmly established before one can conclude that gain in safety is within reach. This evidence concerns the gene F11 and hyperinsulinemic hypoglycemia, familial, 4.